BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 9278394)

  • 1. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural aspects of the gastric H,K ATPase.
    Shin JM; Besancon M; Bamberg K; Sachs G
    Ann N Y Acad Sci; 1997 Nov; 834():65-76. PubMed ID: 9405786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the site of inhibition by omeprazole of a alpha-beta fusion protein of the H,K-ATPase using site-directed mutagenesis.
    Lambrecht N; Corbett Z; Bayle D; Karlish SJ; Sachs G
    J Biol Chem; 1998 May; 273(22):13719-28. PubMed ID: 9593713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The site of action of pantoprazole in the gastric H+/K(+)-ATPase.
    Shin JM; Besancon M; Simon A; Sachs G
    Biochim Biophys Acta; 1993 Jun; 1148(2):223-33. PubMed ID: 8389196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
    Lorentzon P; Bayati A; Lee H; Andersson K
    Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
    [No Abstract]   [Full Text] [Related]  

  • 9. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric acid secretion: activation and inhibition.
    Sachs G; Prinz C; Loo D; Bamberg K; Besancon M; Shin JM
    Yale J Biol Med; 1994; 67(3-4):81-95. PubMed ID: 7502535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of the gastric acid pump: the H+,K+ ATPase.
    Sachs G; Shin JM; Briving C; Wallmark B; Hersey S
    Annu Rev Pharmacol Toxicol; 1995; 35():277-305. PubMed ID: 7598495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane topology and omeprazole labeling of the gastric H+,K(+)-adenosinetriphosphatase.
    Besancon M; Shin JM; Mercier F; Munson K; Miller M; Hersey S; Sachs G
    Biochemistry; 1993 Mar; 32(9):2345-55. PubMed ID: 8382947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Discovery and development of the proton pump inhibitor].
    Igata H; Okabe S
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of inhibition of H+, K(+)-ATPase by sodium 2-[[4-(3- methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810).
    Nochi S; Yokoyama Y; Narukawa M; Ebine K; Murahashi M; Kawakami Y; Asakawa N; Sato T
    Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):552-8. PubMed ID: 8882453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topology and sites in the H,K-ATPase.
    Sachs G; Shin JM; Besancon M; Munson K; Hersey S
    Ann N Y Acad Sci; 1992 Nov; 671():204-16. PubMed ID: 1337673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase.
    Morii M; Hamatani K; Takeguchi N
    Biochem Pharmacol; 1995 Jun; 49(12):1729-34. PubMed ID: 7598734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.